Lamivudina Mylan

Lamivudine, the active ingredient in Lamivudina Mylan, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral tablet for oral use. It is prescribed to treat HIV‑1 infection and chronic hepatitis B in both adults and children as part of approved therapeutic regimens.

GNH USA supplies Lamivudina Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics across multiple regions and timely delivery to meet patient needs globally.

Lamivudine is an NRTI used to manage viral infections that rely on reverse transcriptase.

- HIV‑1 infection (adults): Reduces viral load as part of combination antiretroviral therapy. - HIV‑1 infection (children): Suppresses viral replication in pediatric patients within approved regimens. - Chronic hepatitis B infection: Inhibits hepatitis B virus replication, improving liver function and disease outcomes.

Lamivudine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Fatigue: general tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Lactic acidosis: metabolic disturbance requiring immediate medical attention. - Severe hepatomegaly with steatosis: liver enlargement with fat accumulation. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

When prescribing lamivudine, clinicians should observe several precautionary measures to ensure patient safety.

- Monitor liver function: assess baseline enzymes and repeat during therapy. - Assess renal function: adjust dosing in patients with impaired clearance. - Screen for hepatitis B co‑infection: evaluate risk of flare upon discontinuation. - Counsel on adherence: missed doses can lead to resistance development. - Avoid use in patients with known hypersensitivity to lamivudine or its excipients. - Store at ambient temperature below 25 °C: keep in the original packaging, protect from moisture and light.

Lamivudine can interact with other medicines, influencing efficacy or toxicity.

Major Interactions (Avoid): - Didanosine: combined use increases risk of pancreatitis. - Stavudine: co‑administration may enhance peripheral neuropathy. - Zidovudine: concurrent therapy can augment mitochondrial toxicity.

Moderate Interactions (Monitor Closely): - Alcohol: may exacerbate liver toxicity, requiring monitoring. - Antacids containing aluminum or magnesium: can affect lamivudine absorption. - Nephrotoxic agents: monitor renal function when used together.